{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:47:12Z","timestamp":1792021632703,"version":"4.4.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","annallergy.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.anai.2024.09.016","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T02:30:22Z","timestamp":1728527422000},"page":"9-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Novel asthma treatments"],"prefix":"10.1016","volume":"134","author":[{"given":"Lior","family":"Seluk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea E.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Rhoads","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3505-2946","authenticated-orcid":false,"given":"Michael E.","family":"Wechsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2024.09.016_bib0001","unstructured":"Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2024. Updated May 2024. Accessed September 16, 2024. Available from: www.ginasthma.org."},{"issue":"11","key":"10.1016\/j.anai.2024.09.016_bib0002","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1111\/all.14526","article-title":"Role of IL-25, IL-33, and TSLP in triggering united airway diseases toward type 2 inflammation","volume":"75","author":"Hong","year":"2020","journal-title":"Allergy"},{"issue":"18","key":"10.1016\/j.anai.2024.09.016_bib0003","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","article-title":"Efficacy and safety of itepekimab in patients with moderate-to-severe asthma","volume":"385","author":"Wechsler","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.anai.2024.09.016_bib0004","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","article-title":"Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial","volume":"9","author":"Rabe","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.anai.2024.09.016_bib0005","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaci.2021.03.044","article-title":"Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial","volume":"148","author":"Kelsen","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"26","key":"10.1016\/j.anai.2024.09.016_bib0006","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.anai.2024.09.016_bib0007","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.anai.2024.09.016_bib0008","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(18)30184-X","article-title":"Tralokinumab for severe, uncontrolled asthma (Stratos 1 and Stratos 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials","volume":"6","author":"Panettieri","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.anai.2024.09.016_bib0009","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two Phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.anai.2024.09.016_bib0010","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMoa1106469","article-title":"Lebrikizumab treatment in adults with asthma","volume":"365","author":"Corren","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.anai.2024.09.016_bib0011","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.anai.2024.09.016_bib0012","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jaip.2024.02.007","article-title":"Lebrikizumab in uncontrolled asthma: reanalysis in a well-defined Type 2 population","volume":"12","author":"Corren","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2024.09.016_bib0013","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bcp.15002","article-title":"A phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma","volume":"88","author":"Singh","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.anai.2024.09.016_bib0014","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/ni805","article-title":"Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP","volume":"3","author":"Soumelis","year":"2002","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.09.016_bib0015","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jaci.2021.05.033","article-title":"TSLP disease-associated genetic variants combined with airway TSLP expression influence asthma risk","volume":"149","author":"Murrison","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"19","key":"10.1016\/j.anai.2024.09.016_bib0016","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2024.09.016_bib0017","first-page":"A6996","article-title":"A multiple ascending-dose study with verekitug, a novel antibody to the human thymic stromal lymphopoietin receptor, in adults with asthma","volume":"209","author":"Singh","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.anai.2024.09.016_bib0018","doi-asserted-by":"crossref","first-page":"e13864","DOI":"10.1111\/cts.13864","article-title":"A first-in-human, single and multiple dose study of lunsekimig, a novel anti-TSLP\/anti-IL-13 NANOBODY(R) compound, in healthy volunteers","volume":"17","author":"Deiteren","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.anai.2024.09.016_bib0019","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.addr.2021.02.017","article-title":"Dry powder pharmaceutical biologics for inhalation therapy","volume":"172","author":"Chang","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"10.1016\/j.anai.2024.09.016_bib0020","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.jaci.2022.12.815","article-title":"Elarekibep (PRS-060\/AZD1402), a new class of inhaled Anticalin medicine targeting IL-4Ra for type 2 endotype asthma","volume":"151","author":"Matschiner","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2024.09.016_bib0021","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.2147\/DDDT.S354291","article-title":"Characterization of selective and potent JAK1 inhibitors intended for the inhaled treatment of asthma","volume":"16","author":"Nilsson","year":"2022","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.anai.2024.09.016_bib0022","first-page":"A4342","article-title":"GDC-0214 is a potent inhaled JAK inhibitor with efficacy in multiple pre-clinical models of Th2 inflammation: a perspective on use of in vivo rodent models for early phase drug discovery","volume":"209","author":"Rinderknecht Eller","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.anai.2024.09.016_bib0023","doi-asserted-by":"crossref","first-page":"AB142","DOI":"10.1016\/j.jaci.2023.11.470","article-title":"Safety and pharmacokinetics of single ascending doses of KN-002 in healthy volunteers and multiple ascending doses of KN-002 in subjects with mild asthma","volume":"153","author":"OBrien","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2024.09.016_bib0024","doi-asserted-by":"crossref","DOI":"10.1177\/20406207231205431","article-title":"Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study","volume":"14","author":"Kuter","year":"2023","journal-title":"Ther Adv Hematol"},{"issue":"8","key":"10.1016\/j.anai.2024.09.016_bib0025","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.jid.2024.02.023","article-title":"Efficacy and safety of rilzabrutinib in pemphigus: PEGASUS Phase 3 randomized study","volume":"144","author":"Murrell","year":"2024","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.anai.2024.09.016_bib0026","first-page":"A7002","article-title":"Efficacy and safety of rilzabrutinib - a novel oral treatment in asthma: results from a double blind placebo controlled phase 2 study","volume":"209","author":"Laidlaw","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.anai.2024.09.016_bib0027","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jaci.2023.05.014","article-title":"Safety and Efficacy of dexpramipexole in Eosinophilic Asthma (EXHALE): a randomized controlled trial","volume":"152","author":"Siddiqui","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2024.09.016_bib0028","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/bjd\/ljad240","article-title":"Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial","volume":"189","author":"Weidinger","year":"2023","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2024.09.016_bib0029","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jaci.2021.08.013","article-title":"JAK inhibitors for asthma","volume":"148","author":"Georas","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.09.016_bib0030","doi-asserted-by":"crossref","first-page":"15038","DOI":"10.1038\/s41598-017-11868-9","article-title":"A new antagonist for CCR4 attenuates allergic lung inflammation in a mouse model of asthma","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.anai.2024.09.016_bib0031","article-title":"FLX193: a potent, selective CCR4 antagonist for allergic disorders","volume":"202","author":"Jorapur","year":"2019","journal-title":"J Immunol"},{"key":"10.1016\/j.anai.2024.09.016_bib0032","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2050-6511-14-14","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study","volume":"14","author":"Cahn","year":"2013","journal-title":"BMC Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.anai.2024.09.016_bib0033","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/eji.201646450","article-title":"GATA-3-specific DNAzyme - a novel approach for stratified asthma therapy","volume":"47","author":"Garn","year":"2017","journal-title":"Eur J Immunol"},{"issue":"2","key":"10.1016\/j.anai.2024.09.016_bib0034","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jaci.2021.10.035","article-title":"The Precision Interventions for Severe and\/or Exacerbation-Prone (PrecISE) Asthma Network: an overview of Network organization, procedures, and interventions","volume":"149","author":"Georas","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2024.09.016_bib0035","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2147\/JAA.S337284","article-title":"Efficacy and safety of masitinib in corticosteroid-dependent severe asthma: a randomized placebo-controlled trial","volume":"15","author":"Davidescu","year":"2022","journal-title":"J Asthma Allergy"},{"issue":"1","key":"10.1016\/j.anai.2024.09.016_bib0036","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12931-016-0347-2","article-title":"A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma","volume":"17","author":"Harris","year":"2016","journal-title":"Respir Res"},{"issue":"3","key":"10.1016\/j.anai.2024.09.016_bib0037","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1164\/rccm.202001-0133OC","article-title":"A Phase 2a, Double-Blind, Placebo-controlled Randomized Trial of Inhaled TLR9 agonist AZD1419 in Asthma","volume":"203","author":"Psallidas","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.anai.2024.09.016_bib0038","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.jaci.2022.03.001","article-title":"Fevipiprant in CRSwNP and comorbid asthma: wrong target population or wrong PGD(2) receptor?","volume":"149","author":"Cahill","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.09.016_bib0039","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12931-018-0912-y","article-title":"Efficacy and safety of antagonists for chemoattractant receptor-homologous molecule expressed on Th2 cells in adult patients with asthma: a meta-analysis and systematic review","volume":"19","author":"Yang","year":"2018","journal-title":"Respir Res"},{"issue":"5","key":"10.1016\/j.anai.2024.09.016_bib0040","first-page":"e24641","article-title":"Efficacy and safety of fevipiprant in asthma: a review and meta-analysis","volume":"14","author":"Jahangir","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.anai.2024.09.016_bib0041","unstructured":"Avalo announces topline data from phase 2 PEAK trial for AVTX-002 (quisovalimab) in patients with non-eosinophilic asthma. Avalo Therapeutics. Accessed August 15, 2024. Available at: https:\/\/ir.avalotx.com\/press-releases\/detail\/173."},{"issue":"5","key":"10.1016\/j.anai.2024.09.016_bib0042","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.jaci.2021.12.759","article-title":"Phase 3b randomized controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER)","volume":"149","author":"Gevaert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2024.09.016_bib0043","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.chest.2022.02.038","article-title":"Results of a phase 2b trial with GB001, a prostaglandin D(2) receptor 2 antagonist, in moderate to severe eosinophilic asthma","volume":"162","author":"Moss","year":"2022","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.anai.2024.09.016_bib0044","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/cea.12244","article-title":"Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial","volume":"44","author":"Neighbour","year":"2014","journal-title":"Clin Exp Allergy"},{"issue":"7","key":"10.1016\/j.anai.2024.09.016_bib0045","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220236","article-title":"Realigning the LIGHT signaling network to control dysregulated inflammation","volume":"219","author":"Ware","year":"2022","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.anai.2024.09.016_bib0046","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.4049\/jimmunol.1500356","article-title":"The TNF family molecules LIGHT and lymphotoxin alphabeta induce a distinct steroid-resistant inflammatory phenotype in human lung epithelial cells","volume":"195","author":"da Silva Antunes","year":"2015","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.anai.2024.09.016_bib0047","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2014.12.1936","article-title":"Tumor necrosis factor superfamily 14 (LIGHT) controls thymic stromal lymphopoietin to drive pulmonary fibrosis","volume":"136","author":"Herro","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2024.09.016_bib0048","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nm.2356","article-title":"The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodeling","volume":"17","author":"Doherty","year":"2011","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.anai.2024.09.016_bib0049","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1164\/rccm.201212-2318OC","article-title":"Randomized, double-blind, placebo-controlled study of Brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma","volume":"188","author":"Busse","year":"2013","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120624015527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120624015527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T10:27:04Z","timestamp":1735640824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120624015527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1081120624015527"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2024.09.016","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel asthma treatments","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2024.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}